诺和诺德据悉正寻求拓宽日本患者获取减肥药的渠道。由于严格的报销规定和有限的处方权限,日本在引进GLP-1类肥胖药物方面受到限制,这在临床需求与更广泛的患者需求之间造成了缺口。
诺和诺德据悉正寻求拓宽日本患者获取减肥药的渠道。由于严格的报销规定和有限的处方权限,日本在引进GLP-1类肥胖药物方面受到限制,这在临床需求与更广泛的患者需求之间造成了缺口。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.